Masimo Corp. Stock
Masimo Corp. Stock
Pros and Cons of Masimo Corp. in the next few years
Pros
Cons
Performance of Masimo Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Masimo Corp. | 0.650% | 1.961% | 1.961% | 9.244% | 40.288% | 1.430% | -10.190% |
| Haemonetics Corp. | 2.480% | 5.983% | 30.252% | - | -9.489% | - | - |
| Bio-Rad Labs Inc. A | -2.640% | -6.515% | 16.091% | 31.548% | -0.969% | -26.525% | -46.792% |
| CONMED Corp. | 0.670% | -1.316% | -3.846% | -39.024% | -14.286% | -74.576% | -72.477% |
Comments
News
This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition
On February 17, 2026, Bridger Management disclosed in a Securities and Exchange Commission (SEC) filing that it sold out its entire position in Masimo (NASDAQ:MASI).
According to a Securities and
This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement
On February 17, 2026, Parkman Healthcare Partners disclosed a new position in Masimo Corporation (NASDAQ:MASI), acquiring 200,000 shares in the fourth quarter worth an estimated $26.01 million at
Naya Capital Adds Masimo Shares
According to an SEC filing dated Feb. 18, Naya Capital Management UK Ltd disclosed a new position in Masimo (NASDAQ:MASI), acquiring nearly 1.6 million shares.
Masimo is a leading provider of


